Cargando…

Initial Physician Experience with [(18)F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan

BACKGROUND: Brain amyloid is a neuropathological hallmark of Alzheimer’s disease (AD). By visualizing brain amyloid, positron emission tomography (PET) may influence the diagnostic assessment and management of patients with cognitive impairment. OBJECTIVE: As part of a Japanese post-approval study t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hattori, Naoya, Sherwin, Paul, Farrar, Gill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2020
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369136/ https://www.ncbi.nlm.nih.gov/pubmed/32715277 http://dx.doi.org/10.3233/ADR-190150

Ejemplares similares

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
por: Ikonomovic, Milos D., et al.
Publicado: (2016)

Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
por: Thal, Dietmar Rudolf, et al.
Publicado: (2018)

Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Software compatibility analysis for quantitative measures of [(18)F]flutemetamol amyloid PET burden in mild cognitive impairment
por: Pemberton, Hugh G., et al.
Publicado: (2023)

Author Correction: Concordance in detecting amyloid positivity between (18)F-florbetaben and (18)F-flutemetamol amyloid PET using quantitative and qualitative assessments
por: Cho, Soo Hyun, et al.
Publicado: (2021)

Amyloid-Targeting PET Tracer [(18)F]Flutemetamol Accumulates in Atherosclerotic Plaques
por: Hellberg, Sanna, et al.
Publicado: (2019)

Validation of an electronic image reader training programme for interpretation of [(18)F]flutemetamol β-amyloid PET brain images
por: Buckley, Christopher J., et al.
Publicado: (2017)

Clinical significance of focal ß-amyloid deposition measured by (18)F-flutemetamol PET
por: Kim, Si Eun, et al.
Publicado: (2020)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Visual assessment of [(18)F]flutemetamol PET images can detect early amyloid pathology and grade its extent
por: Collij, Lyduine E., et al.
Publicado: (2021)

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images
por: Bucci, Marco, et al.
Publicado: (2021)

Is Amyloid Burden Measured by (18)F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?
por: Müller, Ebba Gløersen, et al.
Publicado: (2022)

Appropriate reference region selection of (18)F-florbetaben and (18)F-flutemetamol beta-amyloid PET expressed in Centiloid
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Infrequent false positive [(18)F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
por: Ikonomovic, Milos D., et al.
Publicado: (2018)

Assessment of perfusion deficit with early phases of [(18)F]PI-2620 tau-PET versus [(18)F]flutemetamol-amyloid-PET recordings
por: Völter, Friederike, et al.
Publicado: (2022)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?
por: Farrar, Gill, et al.
Publicado: (2019)

Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [(18)F] flutemetamol amyloid PET study
por: Hanseeuw, Bernard J., et al.
Publicado: (2020)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Early-phase (18)F-FP-CIT and (18)F-flutemetamol PET were significantly correlated
por: An, Young-Sil, et al.
Publicado: (2021)

Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer’s disease with PET imaging agents (18)F-flutemetamol and (18)F-florbetaben
por: Son, Hye Joo, et al.
Publicado: (2018)

Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies
por: Heeman, Fiona, et al.
Publicado: (2019)

Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019)

Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods
por: Battle, Mark R., et al.
Publicado: (2018)

A Case of Early Onset Alzheimer's Disease Diagnosed by (18)F Flutemetamol PET Image
por: Kim, Jeong-Hoon, et al.
Publicado: (2018)

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2019)

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

The clinical safety, biodistribution and internal radiation dosimetry of flutemetamol ((18)F) injection in healthy Japanese adult volunteers
por: Senda, Michio, et al.
Publicado: (2015)

Diagnostic effectiveness of quantitative [(18)F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus
por: Leinonen, Ville, et al.
Publicado: (2014)

In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamol
por: Snellman, Anniina, et al.
Publicado: (2014)

Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease
por: Salloway, Stephen, et al.
Publicado: (2017)

Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer’s Disease
por: Hatashita, Shizuo, et al.
Publicado: (2019)

(18)F-flutemetamol positron emission tomography in cardiac amyloidosis
por: Papathanasiou, Maria, et al.
Publicado: (2020)

Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer’s disease
por: Ikonomovic, Milos D., et al.
Publicado: (2020)

Quantitative Evaluation of (18)F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
por: Matsuda, Hiroshi, et al.
Publicado: (2021)

Cerebellar and Cerebral Amyloid Visualized by [(18)F]flutemetamol PET in Long-Term Hereditary V30M (p.V50M) Transthyretin Amyloidosis Survivors
por: Uneus, Erica Irene, et al.
Publicado: (2022)

Longitudinal changes in (18)F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations
por: Luckett, Emma S., et al.
Publicado: (2023)

[(18)F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [(18)F]-Fludeoxyglucose
por: Kalheim, Lisa Flem, et al.
Publicado: (2018)

Image reconstruction methods affect software-aided assessment of pathologies of [(18)F]flutemetamol and [(18)F]FDG brain-PET examinations in patients with neurodegenerative diseases
por: Lindström, Elin, et al.
Publicado: (2020)

Simulating the effect of cerebral blood flow changes on regional quantification of [(18)F]flutemetamol and [(18)F]florbetaben studies
por: Heeman, Fiona, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2gldeu7nhe7perhvav311b014u